Teva-Spironolactone/HCTZ 50 mg / 50 mg – DIN 00657182
Teva-Spironolactone/HCTZ is Hydrochlorothiazide and Spironolactone 50 mg / 50 mg (tablet), sold in Canada. It is used for heart failure. It is supplied by Teva Canada Limited. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.
Sold in Canada
Hydrochlorothiazide and Spironolactone 50 mg / 50 mg
- Brand
- Teva-Spironolactone/HCTZ
- Strength
- Hydrochlorothiazide 50 mg / Spironolactone 50 mg
- Used for
- Heart failure
- Form
- Tablet
- Manufacturer
- Teva Canada Limited
- Drug class
- Aldosterone blocker (heart and blood pressure medicine)
- Sold in
- Canada
- DIN
- 00657182
Source: Health Canada's Drug Product Database. Last checked .
Report a mistake
What is Spironolactone and Hydrochlorothiazide used for?
Spironolactone and Hydrochlorothiazide is used for heart failure.
- Medicine type
- Aldosterone blocker (heart and blood pressure medicine); thiazide diuretic (water pill)
Official uses from the US prescribing label
Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided.
Spironolactone and hydrochlorothiazide tablets are indicated for:
Edematous conditionsfor patients with:
Congestive heart failure:
- For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures;
- The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate;
- The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate.
Cirrhosis of the liver accompanied by edema and/or ascites:
- Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium.
The nephrotic syndrome:
- For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response.
Essential hypertension:
- For patients with essential hypertension in whom other measures are considered inadequate or inappropriate;
- In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate;
- Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Usage in Pregnancy
The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia.
Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.
From the FDA-approved label on DailyMed (published Sep 14, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your medicine? Check the box
- The box or bottle shows DIN 00657182.
- It names Teva-Spironolactone/HCTZ, Hydrochlorothiazide and Spironolactone 50 mg / 50 mg.
- A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.
Sold in Canada as Teva-Spironolactone/HCTZ by Teva Canada Limited.
In Canada: prescription only.
Ingredients
Active: Hydrochlorothiazide, Spironolactone
Other Spironolactone and Hydrochlorothiazide pills
- M 41 Spironolactone and Hydrochlorothiazide 25 mg / 25 mg White, round, 10 mm Used for heart failure
- MP 40 Spironolactone and Hydrochlorothiazide 25 mg / 25 mg White, round, 10 mm Used for heart failure
- G 5014 Spironolactone and Hydrochlorothiazide 25 mg / 25 mg Brown, round, 10 mm Used for heart failure
- UpArrowheadK4 Spironolactone and Hydrochlorothiazide 25 mg / 25 mg Brown, round, 10 mm Used for heart failure
- No picture yet DIN 00613231 Hydrochlorothiazide and Spironolactone 25 mg / 25 mg Teva-Spironolactone/HCTZ, Tablet, sold in Canada Used for heart failure